Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data.
It is shown that longitudinal patient data help prioritize drug combinations for clinical testing across immune-mediated diseases, and anti-TNF and anti-interleukin 6 receptor therapy emerges as highly complementary in rheumatoid arthritis.